Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

[1]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[2]  B. Esterni,et al.  Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  C. Nabhan.  Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Steinberg,et al.  A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[7]  M. Somerfield,et al.  American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Milano,et al.  Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel–erlotinib and 5-fluoro-5′-deoxyuridine , 2006, Anti-cancer drugs.

[10]  P. Schellhammer,et al.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Klotz.  Combined androgen blockade: an update. , 2006, The Urologic clinics of North America.

[12]  E. Crawford,et al.  Screening for prostate cancer in 2006: PSA in the 21st century. , 2006, North Carolina medical journal.

[13]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Tindall,et al.  Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.

[15]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[16]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[17]  E. Crawford,et al.  Screening for prostate cancer. , 2004, Clinical prostate cancer.

[18]  A. Angelucci,et al.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures , 2003, Journal of Cancer Research and Clinical Oncology.

[19]  H. Levin,et al.  Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. , 2001, Human pathology.

[20]  Edward S. Kim,et al.  Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.

[21]  C. Mitsiades,et al.  Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer , 2001, Expert opinion on investigational drugs.

[22]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[23]  C. Logothetis,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0253 , 2022 .

[24]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[25]  D. Djakiew,et al.  Inhibition of chemomigration of a human prostatic carcinoma cell (TSU‐pr1) line by inhibition of epidermal growth factor receptor function , 1996, The Prostate.

[26]  D. Djakiew,et al.  Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone , 1996, The Prostate.

[27]  C. Cordon-Cardo,et al.  Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  L. Tanoue,et al.  Erlotinib in Previously Treated Non-Small-Cell Lung Cancer , 2007 .

[29]  W. Fantl,et al.  Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.